Trial reportBMC nephrology2026
Predictive role of baseline serum creatinine-to-cystatin C ratio for renal dysfunction incidence in patients with acute ischemic stroke.
Trial report in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04290494 (Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007 2017: Analysis of China National Stroke Registry (CNSR) I, II, and III
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe serum creatinine-to-cystatin C (Cr/CysC) ratio is associated with the prognosis of various diseases. Renal dysfunction in patients with stroke is associated with an increased risk of mortality and poor functional outcomes. This study aimed to evaluate the predictive role of the serum Cr/CysC ratio for renal dysfunction occurrence in patients with acute ischemic stroke (AIS).
methodsWe enrolled patients from the China National Stroke Registry-Ⅲ (CNSR-Ⅲ) database, who were classified into four groups (Q1–Q4, from low to high) according to the quartiles of the baseline serum Cr/CysC ratio. The main endpoints were occurrence of incident chronic kidney disease (CKD) and rapid decline in kidney function (RDKF) at 1 year after AIS. Multivariate logistic regression models were applied to analyze the relationship between the Cr/CysC ratio and main endpoints.
resultsAfter adjusting for confounding factors and using Q1 as the reference, the Q3 and Q4 quartiles of the baseline serum Cr/CysC ratio were negatively associated with incident CKD risk at 1 year (Q3 vs. Q1: adjusted odds ratio [aOR] 0.41, 95% confidence interval [CI] 0.21–0.80, P = 0.009; Q4 vs. Q1: aOR 0.39, 95%CI 0.18–0.81, P = 0.012). Furthermore, the Q2–Q4 quartiles of the baseline serum Cr/CysC ratio were negatively associated with RDKF risk at 1 year (Q2 vs. Q1: aOR 0.77, 95%CI 0.63–0.94, P = 0.009; Q3 vs. Q1: aOR 0.62, 95%CI 0.50–0.77, P < 0.001; Q4 vs. Q1: aOR 0.44, 95%CI 0.34–0.56, P < 0.001). The concordance statistic was 0.78 for incident CKD and 0.67 for RDKF.
conclusionsA lower baseline serum Cr/CysC ratio was associated with a higher risk of incident CKD and RDKF 1 year after AIS. The serum Cr/CysC ratio may serve as an important biomarker for predicting renal function outcomes after AIS.
trial registrationThis CNSR-Ⅲ study was registered at ClinicalTrials.gov (identifier: NCT04290494).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.